BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation

  • Authors:
    • Yang‑Ling Li
    • Ming‑Jun Rao
    • Ning‑Yu Zhang
    • Lin‑Wen Wu
    • Neng‑Ming Lin
    • Chong Zhang
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/etm.2019.7500
  • Pages: 4547-4553
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is associated with some of the highest cancer‑associated mortality rates. Histone deacetylase (HDAC) inhibitors anti‑HCC activities have been shown to promote Snail‑induced metastasis. In the present study, it was shown that BAY 87‑2243, a hypoxia‑inducible transcription factor‑1α inhibitor, could enhance the anti‑HCC effects of HDAC inhibitors, including trichostatin A and vorinostat. In addition, BAY 87‑2243 plus HDAC inhibitors exhibited synergistic cytotoxicity and induced significant cell death in Hep3B cells. Additionally, BAY 87‑2243 combined with HDAC inhibitors‑treated Hep3B cells formed fewer and smaller colonies as compared with either the control or single agent‑treated cells. Furthermore, glycogen synthase kinase‑3β might be involved in the enhanced cell death induced by BAY 87‑2243 plus HDAC inhibitors. The present data also indicated that BAY 87‑2243 combined with HDAC inhibitors could suppress the migration of Hep3B cells, and BAY 87‑2243 could reverse the HDAC inhibitor‑induced Snail activation in Hep3B cells. In conclusion, BAY 87‑2243 combined with HDAC inhibitors might be an attractive chemotherapy strategy for HCC therapy.
View Figures
View References

Related Articles

Journal Cover

June-2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos
Li Y, Rao M, Zhang N, Wu L, Lin N and Zhang C: BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation. Exp Ther Med 17: 4547-4553, 2019
APA
Li, Y., Rao, M., Zhang, N., Wu, L., Lin, N., & Zhang, C. (2019). BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation. Experimental and Therapeutic Medicine, 17, 4547-4553. https://doi.org/10.3892/etm.2019.7500
MLA
Li, Y., Rao, M., Zhang, N., Wu, L., Lin, N., Zhang, C."BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation". Experimental and Therapeutic Medicine 17.6 (2019): 4547-4553.
Chicago
Li, Y., Rao, M., Zhang, N., Wu, L., Lin, N., Zhang, C."BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4547-4553. https://doi.org/10.3892/etm.2019.7500